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Objectives. This study sought o assess the long-term clinical 
consequences of reocclusion after coronary thrombolysis. 
Background. After acute myocardial infarction successfully 
treated with thrombolysis, reocclusion occurs in -30% of patients 
and leads to poorer in-hospital outcome. However, the long-term 
effects of reocclusion are unknown. 
Methods. Three hundred patients with no history of coronary 
surgery and with a patent infarct-related artery at coronary 
angiography within 48 h after thrombolysis were enrolled in the 
Antithrombotics in the Prevention of Reocclusion in Coronary 
Thrombolysis (APRICOT) trial. At a mean (-+SD) of 77 -+ 23 days 
after thrombolysis, 248 patients (87%) underwent follow-up an- 
giograpby. Reocclusion was observed in 71 (29%) of 248 patients. 
To compare outcome between 71 patients with and 177 without 
reocclusion an analysis of event-free survival, defined as a clinical 
course without death, reinfarction and revascularization, was 
performed. 
Results. Over a 3-year follow-up eriod, event-free survival was 
significantly better in patients without reocclusion: At 1 year it 
was 63% for patients with and 83% for those without reoeclusion 
(p < 0.001). In the first year, two or more cardiac-related events 
occurred in 24% of patients with and 6% of those without 
reocclusion (p < 0.001). Patients with reocclusion had a markedly 
higher reinfarction and revascnlarization rate. At 1 year the 
reinfarction rate was 23% for patients with and 5% for those 
without reocclusion (p < 0.001). 
Conclusions. This analysis shows the adverse influence of 
reocclusion on long-term clinical outcome in relation to reinfarc- 
tion and need for revascularization. To further optimize prognosis 
after thrombolysis, prevention of reocclusion should become a 
main priority. Future research should focus on the criteria and 
timing of elective revascularization procedures in the prevention 
of coronary reocclusion. 
(J Am Coil Cardiol 1995;26:1440-4) 
In the past decade, thrombolytic therapy has become the 
cornerstone of treatment for acute transmural myocardial 
infarction. In 80% of all treated patients, recanalization f the 
infarct-related artery is eventually achieved (1). However, 
several studies (2-8) have demonstrated that reocclusion 
occurs in 5% to 30% of patients after successful thrombolysis. 
Reocclusion has proved to be associated with an adverse 
short-term clinical outcome (3) and impaired residual eft 
ventricular function (3,9), the most important prognostic factor 
after myocardial infarction after thrombolysis (10). The benefit 
of thrombolytic therapy--improvement of both short- and 
long-term survival--could therefore be optimized by the pre- 
vention of reocclusion. Routine invasive strategies after throm- 
bolysis have not been shown to improve clinical outcome (11). 
There have been several studies (28) specifically addressing 
coronary reocclusion and the intermediate-term effects of oral 
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antithrombotic therapy on reocclusion. These studies may 
provide insight into the long-term effects of reocclusion after 
coronary thrombolysis. 
Several trials (12-14) have been conducted to determine 
long-term survival after thrombolytic therapy. To our knowl- 
edge, this report is the first follow-up study to assess the effects 
of reocclusion on long-term clinical outcome. The data are 
derived from the Antithrombotics in the Prevention of Reoc- 
clusion in Coronary Thrombolysis (APRICOT) trial (2). 
Methods  
Study protocol. A detailed escription of the APRICOT 
study protocol and criteria used to select patients has previ- 
ously been published (2). In brief, 300 patients -<70 years old 
with no history of coronary surgery were enrolled between 
August 15, 1987 and June 30, 1991. They presented with chest 
pain lasting >30 rain and <4 h combined with a minimum of 
0.2 mV of ST segment elevation i  two contiguous electrocar- 
diographic (ECG) leads. They received thrombolytic therapy 
with either streptokinase or anistreplase followed by a fixed 
dose of intravenous heparin (20,000 U/24 h). Downward ose 
adjustments were made only when the activated partial throm- 
boplastin time exceeded 2.5 times baseline values. Standard 
coronary care treatment was given (15). Within 48 h after the 
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Figure 1. Reasons for not undergoing follow-up coronary angiography 
after 3 months. IRA = infarct-related artery. 
start of thrombolytic treatment, coronary angiography showed 
grade 1 to 3 stenosis of the infarct-related artery according to 
the criteria defined by the European Cooperative Study Group 
(16). European Cooperative Study Group grades 1 to 3 are 
identical to Thrombolysis in Myocardial Infarction (TIMI) 
grade 3 flow. Sixteen patients were retrospectively judged to 
have an occluded infarct-related artery and were not included 
in the study (Fig. 1). 
All 284 patients with a patent infarct-related artery were 
randomized totreatment with 325 mg of aspirin daily, couma- 
din (international normalized ratio 2.8 to 4.0) or placebo. 
Infarct-related artery status at 3 months was the primary end 
point of the APRICOT trial. Revascularization was performed 
for clinical reasons only. Thirty-six patients did not undergo 
follow-up angiography because of refusal (n - 28), coronary 
bypass urgery (n = 6) or death (n = 2) (Fig. 1). Reocclusion 
was defined as a grade 4 to 5 stenosis (16) and corresponds to 
TIMI flow grades 0 to 2. The culprit lesions of patients 
undergoing angioplasty before the scheduled second angiogra- 
phy were analyzed in the catheterization laboratory immedi- 
ately before the angioplasty procedure. On the basis of results 
of the second angiography, two groups of patients were 
defined: 1) 71 patients with reocclusion; and 2) 177 without 
reocclusion. 
Follow-up. Patients that participated in the APRICOT trial 
were screened for cardiac-related vents over a 3-year follow- 
up period. Medical files were used to study hospital admissions 
for the following reasons: coronary angioplasty, coronary by- 
pass surgery and reinfarction. In addition, survival status of all 
enrolled patients was assessed. Municipal registries and tele- 
phone contact with the patient, general practitioner or rela- 
tives enabled us to complete missing information. 
Clinical end points. Outcome between groups was com- 
pared according to vessel status at the second angiography, and 
clinical information since the day of randomization was used. 
The primary end point of the analysis was event-free survival. 
An event-free follow-up was defined as a clinical course 
without death, reinfarction or readmission for coronary angio- 
plasty or coronary bypass urgery. Criteria for recurrent myo- 
cardial infarction were chest pain accompanied bytypical ECG 
changes combined with an increase in creatine kinase levels 
higher than twice the upper normal imit. 
Statistics. Baseline characteristics are expressed as mean 
value +_ SD and were compared by the Student test. 
Whenever appropriate, the chi-square test was used for other 
comparisons between groups. Event-free survival curves were 
obtained as described by Kaplan and Meier (17). To determine 
the statistical significance of the difference between curves, the 
log-rank test was used. A p value <0.05 was considered 
statistically significant. 
Resu l ts  
Follow-up. Of the 284 patients participating in the 
APRICOT trial, 248 (87%) had a second coronary angiogra- 
phy performed a mean of 77 _+ 23 days after thrombolysis (Fig. 
1). Patients without angiographic foUow-up more often had a 
history of myocardial infarction (17% vs. 6%, p < 0.025), were 
slightly older (60 _+ 7 vs. 56 + 9 years, p < 0.01) and were more 
often female (31% vs. 17%, p < 0.05) (2). The 248 patients 
with both a first and second angiography formed the present 
study group. Follow-up data were collected for a median of 31 
months (25th to 75th percentile, 19 to 46 months) starting on 
the day of randomization. No patient was lost to follow-up. In 
the first follow-up year six patients died. Information on 238 
(98%) of the surviving 242 patients after >1 year of follow-up 
was available. 
Table 1 shows the baseline characteristics of patients with 
and without reocclusion. No statistical differences were ob- 
served. 
Clinical outcome. Figure 2 shows event-free survival in 
patients with and without reocclusion over a 3-year follow-up 
period. In the reocclusion group, the majority of all events 
occurred in the first 3 months. In this short period of time, the 
event-free survival rate decreased to 68% for patients with 
reocclusion compared with 92% for those without reocclusion. 
There was a significant (p < 0.001) overall difference in the 
event-free survival curves, with most of the difference occur- 
ring within the first weeks. At 1 year these percentages were 
63% and 83%, respectively (p < 0.001). Reinfarction rates at 
this stage were 23% and 5%, respectively (p < 0.001). 
Over the entire follow-up period, 19 patients (27%) with 
and 16 patients (9%) without reocclusion had a reinfarction. 
Reinfarction occurred in the same area as the index infarction, 
except in one patient. Proportionally, the reocclusion group 
experienced three times as many reinfarctions (Table 2). Data 
are expressed as event counts rather than event rates because 
of the decreasing follow-up percentage after the first year of 
follow-up. 
In the first year of follow-up the incidence of cardiac- 
related events was 59% for patients with and 24% for those 
without reocclusion (p < 0.001). These rates were similar over 
3 years: 75% for the former and 33% for the latter. Patients 
without reocclusion experienced 39 cardiac-related vents in 
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the first year of follow-up. Forty-four percent of events oc- 
curred within 3 months after andomization, i  contrast to 74% 
of all observed events in patients with reocclusion (p < 0.03). 
At 1 year of follow-up, a clinical course with two or more 
cardiac-related events was seen in 24% of patients with 
compared with 6% of patients without reocclusion (p < 0.001). 
Over the entire follow-up period, multiple vents occurred in 
22 patients (31%) with and 15 patients (9%) without reocclu- 
sion. 
Discussion 
Reoeelusion and event-free survival. To our knowledge, 
this is the first study to demonstrate he sustained adverse 
influence of reocclusion on clinical outcome. The first months 
after successful thrombolysis appear to be of major impor- 
tance: -60% of all cardiac-related events in the reocclusion 
group occurred within 3 months after thrombolytic therapy. 
Although the mortality rate was low, a result of the study 
design (2), there was a marked ifference in event-free survival 
in favor of patients without reocclusion, due to the relatively 
high rate of reinfarction and angioplasty in patients with 
reocclusion. 
Long-term survival after myocardial infarction is primarily 




(n = 177) (n = 71) 
Male (%) 81 87 
Age (yr) 56 -+ 9 57 _+ 9 
Angina pectoris 
<4 wk 52 (29%) 25 (35%) 
->4 wk 33 (19%) 15 (21%) 
Previous myocardial infarction 11 (6%) 4 (6%) 
Time of symptoms (thrombolysis) (h) 2.0 +- 1.0 2.0 _+ 1.1 
Peak creatine kinase (U/liter) 1,545 _+ 1,509 1,567 _+ 1,419 
Study medication 
Aspirin 70 (40%) 23 (23%) 
Coumadin 57 (32%) 24 (34%) 
Placebo 50 (28%) 24 (34%) 
Infarct-related artery 
LAD 71 (40%) 34 (48%) 
LCx 28 (16%) 11 (16%) 
RCA 78 (44%) 26 (37%) 
One-vessel disease 106 (60%) 36 (51%) 
Two-vessel disease 49 (28%) 24 (34%) 
Three-vessel disease 22 (12%) 11 (16%) 
Ejection fraction (%) 51 _+ 10 52 _+ 13 
No. of pts 120 52 
End-systolic volume (ml) 76 _+ 29 73 -- 31 
No. of pts 97 46 
End-diastolic volume (ml) 152 _+ 43 152 _+ 39 
No. of pts 97 46 
Unless otherwise indicated, data presented are mean value _+ SD or number 
(%) of patients (pts). LAD = left anterior descending coronary artery; LCx = 







% Event-free survival 
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.,..,.,. reocclusion 
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! 2 3 
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Figure 2. Event-free survival (defined as a clinical course without 
death, reinfarction rrevascularization) n patients with and without 
reocclusion. The follow-up eriod starts at first coronary angiography 
(within 48 h after successful thrombolysis). 
predicted by the functional status of the left ventricle (18). 
Reocclusion is associated with impaired recovery of left ven- 
tricular function (3,9). These findings strongly suggest hat 
mortality would have been higher if selection criteria had not 
been as strict as in the present study. The 1-year mortality rate 
for the study group was 2.4%. Even over a 3-year follow-up 
period, only 12 (5%) of 248 patients died. Three-year survival 
rates reported by long-term survival trials of thrombolysis vary 
from 84% to 87% (12,14). Because of the low mortality profile, 
the difference in event-free survival might even be slightly 
underestimated. 
Reoeelusion and reinfarction. Reinfarction occurs more 
frequently in patients with than without reocclusion. Our data 
are in accordance with earlier findings (3) showing that most 
symptomatic recurrent ischemic events occur within the first 
days after thrombolytic therapy. The majority of the reocclu- 
sions (78%) are not associated with clinically apparent rein- 
farction. During this period and thereafter, reocclusion islikely 
to occur asymptomatically because of the development of
collateral channels (19). 
Only two of the 15 reinfarctions observed in the first 3 
months did not occur within 10 days. Overall, 84% of the 
reinfarctions in the reocclusion group occurred within 3 
months after enrollment. In contrast, only 20% of the reinfarc- 
tions in patients without reocclusion occurred in the 3-month 
period. Therefore, in this group, 80% of the reinfarctions 
occurred later in the first year and in the second and third 
follow-up year. These reinfarctions are most likely to be 
related to the ongoing atherosclerotic process, whereas the 
early reinfarctions most likely result from rethrombosis after 
thrombolytic therapy (12). 
Reoeclusion and need for revaseularization. Over the en- 
tire follow-up period, revascularizations represented the ma- 
jority of cardiac-related vents. It should be noted that these 
procedures were performed for clinical, not angiographic, 
reasons only. In the reocclusion group, -50% of all angio- 
plasty procedures were performed before the second angiog- 
raphy. The information obtained at angiographic follow-up 
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Table 2. Clinical Events Over 3-Year Follow-Up in Patients With and Without Reocclusion 
Before 2nd Angio 
2nd Angio to 1st yr 2nd yr 3rd yr Total 
No. of pts with reocclusion at risk (n = 71) 71 48 45 27 71 
Death 2 1 2 1 6 (9%) 
Reinfarction 15 1 2 1 19 (27%) 
PTCA 12 6 3 0 21 (30%) 
CABG 2 3 2 0 7 (10%) 
Total 31 11 9 2 53 (75%) 
No. of pts without reocclusion at risk (n = 177) 177 163 147 94 177 
Death 0 3 3 0 6 (3%) 
Reinfarction 3 5 6 2 16 (9%) 
PTCA 12 9 3 0 24 (14%) 
CABG 3 4 4 1 12 (7%) 
Total 18 21 16 3 58 (33%) 
Data presented are number or number (%) of patients (pts). Angio = angiography; CABG = coronary artery bypass 
surgery; PTCA = percutaneous transluminal coronary angioplasty. 
may have caused the physician to perform more revasculariza- 
tions than usual. However, the consequences forthe pattern of 
the event-free survival curves are negligible because the period 
leading up to the second angiography is of greater clinical 
importance. 
Reocclusion and multiple events. Reocclusion has proved 
to be associated with a higher incidence of cardiac-related 
events and hospital admissions. Only 15 (9%) of the 177 
patients without reocclusion had two or more events compared 
with 22 (31%) of 71 with reocclusion. Therefore, nearly 33% of 
patients with reocclusion experienced multiple events. This 
finding, combined with the fact that 37 patients with reocclu- 
sion had no events, indicates that some patients with reocclu- 
sion have a higher risk for a complicated clinical course than 
others. 
Effects of thrombolytic therapy on long-term improvement. 
The results of the present study emphasize the clinical impor- 
tance of an initially and persistently patent infarct-related 
artery comparison with an initially open but reoccluded artery. 
An earlier long-term analysis (20) of the prognostic effects of 
patency included only one angiographic observation per- 
formed 1 month after thrombolysis and also identified patency 
as an important prognostic factor, which proved to be inde- 
pendent of left ventricular function. 
To optimize the results of thrombolytic therapy, a combi- 
nation of two approaches might be successful. 
1. The reocclusion rate should be reduced as much as 
possible. New antithrombotic drugs, such as hirudin and 
hirulog (6,21), may better prevent reocclusion. Identification of 
patients with a high risk for reocclusion would also be of major 
importance. So far, clinical variables have failed to determine 
predictors of reocclusion (22). 
2. Patients with reocclusion might benefit from elective 
angioplasty within a few weeks after myocardial infarction, 
when coronary angioplasty can safely be performed, especially 
if collateral supply is sufficient. Late recanalization may pre- 
vent ventricular dilation (23,24). This ventricular enlargement 
is a compensatory mechanism to restore stroke volume at the 
expense of an increased preload and afterload to the left 
ventricle, which may stimulate further dilation (9,25). It has 
been demonstrated that ventricular enlargement occurs more 
frequently with an occluded than with a patent infarct-related 
artery (9,26,27) and that reperfusion can prevent dilation (28). 
One could argue whether all patients of the reocclusion 
group would have benefited from a recanalization procedure. 
More than 50% of patients with reocclusion had no events over 
a 3-year follow-up period; however, asymptomatic reocclusion 
might have occurred in some of them. An option would be to 
perform coronary angioplasty in a prespecified subgroup. Our 
data show that new cardiac-related vents are most likely to 
occur in patients with an event in the first 3 months. Twenty- 
two new events occurred after angiographic follow-up: 11 
occurred in patients who had already had 1 event. 
In the APRICOT trial (2), a conservative strategy was 
intended: Revascularizations were performed only for reasons 
of recurrent ischemia not responsive to medical anti-ischemic 
treatment. The advantage ofelective angioplasty would be that 
ventricular enlargement would be less extensive than with 
angioplasty performed at the time of symptoms. These options 
should be investigated further, because the optimal benefits of 
thrombolytic therapy have not yet been attained. 
Study limitations. One limitation of the present study 
design is that only those patients who survived the acute phase 
and, in addition, were fit enough to undergo catheterization 
within 48 h, were eligible to enter the study. Furthermore, only 
patients who had a patent infarct-related artery at first angiog- 
raphy and underwent follow-up angiography were included 
in this analysis. This selection bias certainly contributed to the 
low mortality rate observed and may have influenced the number 
of observed events. Another estriction concerns the exclusion of 
patients with coronary bypass urgery before the second an- 
giography. Finally, only patients <-70 years of age participated 
in the trial, which may also have contributed to an underesti- 
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mation of the incidence of cardiac-related vents after success- 
ful thrombolysis. 
Despite the aforementioned restrictions, the number of 
revascularizations might have been lower if a second angiog- 
raphy had not been performed. Generally, symptoms of recur- 
rent ischemia not responding to anti-ischemic treatment would 
be an indication to perform revascularization. In the present 
trial, the information obtained at follow-up angiography may 
have led the physician to follow a less conservative treatment 
strategy. 
Conclusions. The results of the present study demonstrate 
that reocclusion after successful thrombolysis for acute myo- 
cardial infarction is associated with a less favorable long-term 
clinical course. Reocclusion results in a relatively high rate of 
reinfarction and angioplasty procedures during the first 3 
months, drastically affecting event-free survival. The observed 
effect on clinical outcome remains significant over a 3-year 
follow-up period. These findings underscore that both the 
prevention and, possibly, adequate treatment of reocclusion 
should become the main priorities of thrombolytic therapy for 
myocardial infarction. Future research might focus on the 
timing, criteria and results of elective revascularization proce- 
dures. 
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